Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Chronic Hepatitis B
Interventions: ABI-H2158 Reference Formulation, ABI-H2158 Test Formulation; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: ABBV-903 Tablet Form 1, ABBV-903 Tablet Form 2; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy
Interventions: Divalproex Sodium, Depakote®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: East Grand Forks, Minnesota

Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Seizures
Interventions: Levetiracetam; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Nonhematologic Malignancies, Lymphoma
Interventions: Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Liver Transplant Surgery
Interventions: TetraGraph on dominant hand, TetraGraph on non-dominant hand; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Renal Insufficiency
Interventions: Gefapixant; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Postoperative Pain
Interventions: EXPAREL and Local Anesthetics, Oral Opioid and Local Anesthetics; Procedure
Lead sponsor: Bellaire Facial Surgery Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Atlanta, Georgia • Houston, Texas • The Woodlands, Texas

Conditions: Glioblastoma, Gliosarcoma
Interventions: Bevacizumab and Erlotinib; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neoplasms
Interventions: GSK2636771, Enzalutamide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more

Conditions: Lymphangioleiomyomas, Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Food Effect in Healthy Participants
Interventions: E7386; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
Interventions: Gastric Ultrasound Exam; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 99 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Albany, New York + 2 more

Conditions: Major Depressive Disorder
Interventions: LY03005, Pristiq; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Healthy
Interventions: Finasteride Tablets 5 mg, Proscar Tablets 5 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy Participants
Interventions: SAD IMG-004 30mg, SAD IMG-004 100mg, SAD IMG-004 200mg, SAD IMG-004 400mg, SAD IMG-004 600mg, SAD Placebo 30mg, SAD Placebo 100mg, SAD Placebo 200mg, SAD Placebo 400mg, SAD Placebo 600mg, MAD IMG-004 50mg, MAD Placebo 50mg, MAD IMG-004 150mg, MAD Placebo 150mg, MAD IMG-004 300mg, MAD Placebo 300mg, FE IMG-004 150mg; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy
Interventions: Sulfasalazine, GLPG3970; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Healthy
Interventions: fluoxetine HCL 40 mg capsules; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy
Interventions: Krill Oil; Dietary Supplement
Lead sponsor: Aker BioMarine Human Ingredients AS; Industry
Eligibility: 21 Years to 79 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Saint Charles, Missouri • Fargo, North Dakota

Conditions: Pain
Interventions: Acetylsalicylic acid (Aspirin, BAY1019036); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Obesity, Overweight, Type 2 Diabetes
Interventions: LY3549492, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 38
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Greenbrae, California + 33 more

Conditions: Gastroesophageal Reflux
Interventions: rabeprazole sodium; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions

Blood Markers of Early Pancreas Cancer

Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

Sugammadex and Quantitative Monitoring in "Fast-Track Anesthesia" During Liver Transplantation

The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)

Efficacy of EXPAREL in Comparison to Standard of Care for the Treatment of Post Operative Dental Implant Pain

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women

A Food-Effect Study of E7386 in Healthy Participants

Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg

Study to Evaluate IMG-004 in Healthy Participants

Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

Bioequivalence Study of Fluoxetine HCL 40 mg Capsules Under Fasting Conditions

Study to Investigate the Effects of Krill Oil on Fasting Serum Triglycerides

Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers